Residual disease detection and recurrence monitoring*
Guardant Reveal™ is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy.
The test detects circulating tumor DNA (ctDNA ) in blood to inform treatment decisions after surgery and detect recurrence as well. Currently, it is developed for early-stage colorectal cancer with testing for additional cancer types to follow.
The blood-only liquid biopsy test for minimal residual disease detection & recurrence monitoring
Guardant Reveal detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in patients with Stage II and Stage III colorectal cancer (CRC). In addition to detection of MRD, Guardant Reveal can be used to monitor for recurrence of CRC in previously diagnosed patients.
Guardant Reveal for patients with Stage II/III CRC
Post-Surgery
Identify patients at high risk for recurrence
Surveillance
Monitor for early signs of recurrence
Check out this one minute Guardant Reveal™ video which gives you more information on the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy.
Easy to interpret report for MRD detection and recurrence monitoring with a simple blood draw.
A POSITIVE TEST
Indicates that ctDNA is detected & there is a higher chance that the cancer is present.
A NEGATIVE TEST
Indicates that no ctDNA is detected.
Guardant Reveal delivers results in two weeks and does not require tissue to initiate, eliminating the delays associated with assays that require tissue and the challenge of inadequate tissue samples. In addition, Guardant Reveal can be ordered 4 weeks after surgery.
References :
Address:
21 Biopolis Road,
# 03-28, Nucleos,
Singapore 138567.
Telephone:
+65 6018 8504
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED